Current Liabilities
Accrued Expenses
Amgen Accrued Expenses decreased by 10.5% to $16.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.8%, from $17.23B to $16.58B. Over 5 years (FY 2020 to FY 2025), Accrued Expenses shows an upward trend with a 12.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Rising accruals can indicate growing operational scale or timing differences in expense recognition, whereas falling accruals may signal a reduction in operational activity.
Detailed definition
Accrued expenses are liabilities that have been incurred but not yet invoiced or paid by the end of the reporting period...
Peer comparison
Common in large-cap firms; peers often show similar patterns based on payroll cycles and operational scale.
Metric ID:
accrued_expensesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.98B | $9.38B | $10.73B | $10.64B | $10.55B | $11.58B | $12.52B | $12.06B | $13.72B | $14.17B | $15.36B | $14.13B | $13.72B | $14.62B | $17.64B | $17.23B | $15.02B | $16.80B | $18.52B | $16.58B |
| QoQ Change | — | +4.4% | +14.4% | -0.9% | -0.9% | +9.9% | +8.1% | -3.7% | +13.7% | +3.3% | +8.4% | -8.0% | -2.9% | +6.6% | +20.7% | -2.3% | -12.8% | +11.8% | +10.3% | -10.5% |
| YoY Change | — | — | — | — | +17.4% | +23.5% | +16.7% | +13.4% | +30.1% | +22.3% | +22.6% | +17.1% | +0.0% | +3.2% | +14.9% | +22.0% | +9.5% | +14.9% | +5.0% | -3.8% |
Range$8.98B – $18.52B
CAGR+13.8%
Avg YoY Growth+14.3%
Median YoY Growth+15.8%
Accrued Expenses at Other Companies
Frequently Asked Questions
- What is Amgen's accrued expenses?
- Amgen (AMGN) reported accrued expenses of $16.58B in Q1 2026.
- How has Amgen's accrued expenses changed year-over-year?
- Amgen's accrued expenses decreased by 3.8% year-over-year, from $17.23B to $16.58B.
- What is the long-term trend for Amgen's accrued expenses?
- Over 5 years (2020 to 2025), Amgen's accrued expenses has grown at a 12.8% compound annual growth rate (CAGR), from $10.14B to $18.52B.
- What does accrued expenses mean?
- Expenses that have been incurred but for which no invoice has been received or payment made yet.